Copyright
©The Author(s) 2023.
World J Stem Cells. Jun 26, 2023; 15(6): 617-631
Published online Jun 26, 2023. doi: 10.4252/wjsc.v15.i6.617
Published online Jun 26, 2023. doi: 10.4252/wjsc.v15.i6.617
Figure 6 Calycosin-pretreated mesenchymal stem cells improve adriamycin-induced podocyte apoptosis by targeting p-Smad3 expression.
A and B: Protein expression levels of p-Smad3 and Smad3 in mouse podocyte cells (MPC5) detected by Western blot and normalized to control. Data are expressed as the mean ± SD (n = 3). aP < 0.05, bP < 0.001; C-G: Protein expression levels of Bax, Bcl-2, p-Smad3, and Smad3 in Smad3-overexpressing MPC5 cells detected by Western blot and normalized to control. Data are expressed as the mean ± SD (n = 3). bP < 0.001; H-L: Cell apoptosis detected by flow cytometry; M: Graphical abstract (created in BioRender.com). NC: Normal control; ADR: Adriamycin; MSCs: Mesenchymal stem cells; CA: Calycosin; MSCsCA: Mesenchymal stem cells pretreated with calycosin; FSGS: Focal segmental glomerulosclerosis.
- Citation: Hu QD, Tan RZ, Zou YX, Li JC, Fan JM, Kantawong F, Wang L. Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis. World J Stem Cells 2023; 15(6): 617-631
- URL: https://www.wjgnet.com/1948-0210/full/v15/i6/617.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v15.i6.617